Filtered By:
Source: J Korean Med Sci
Vaccination: Covid Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 495 results found since Jan 2013.
Clinical Utility of Sero-Immunological Responses Against SARS-CoV-2 Nucleocapsid Protein During Subsequent Prevalence of Wild-Type, Delta Variant, and Omicron Variant
In conclusion, nucleocapsid antibody provides instructive clues about the immunogenicity of nucleocapsid proteins by different seroconversion rates and titers according to the severity of infection, host immune status, and different variants of concern.PMID:37724496 | DOI:10.3346/jkms.2023.38.e292
Source: J Korean Med Sci - September 19, 2023 Category: General Medicine Authors: Beomki Lee Jae-Hoon Ko Jin Yang Baek Haein Kim Kyungmin Huh Sun Young Cho Cheol-In Kang Doo Ryeon Chung Kyong Ran Peck Eun-Suk Kang Source Type: research
Risk Factors Related to COVID-19 Reinfection and Fatality During the Omicron (BA.1/BA.2) Period in Korea
CONCLUSION: In these data, vaccination history was significantly related to reduced COVID-19 reinfection and severe progression, and scheduled vaccinations were important even with a history of infection.PMID:37644683 | PMC:PMC10462479 | DOI:10.3346/jkms.2023.38.e269
Source: J Korean Med Sci - August 30, 2023 Category: General Medicine Authors: Ju Hee Lee Ji Hae Hwang Eun Jung Jang Ryu Kyung Kim Kil Hun Lee Seon Kyeong Park Jin Gwack Young Joon Park Source Type: research
A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea
CONCLUSION: As the COVID-19 variants and risk group-specific durable efficacy, toxicity (and/or resistance) and optimal dosing of Evusheld remain uncertain, better empirical estimates to inform these values in different epidemiological contexts are needed. These results may help decision-makers prioritize resources toward more equitable and effective COVID-19 control efforts.PMID:37582500 | PMC:PMC10427216 | DOI:10.3346/jkms.2023.38.e250
Source: J Korean Med Sci - August 15, 2023 Category: General Medicine Authors: Youngji Jo Sun Bean Kim Jaehun Jung Source Type: research
COVID-19 Vaccination Status Among Korean Pediatric Population With Comorbidities
J Korean Med Sci. 2023 Aug 14;38(32):e248. doi: 10.3346/jkms.2023.38.e248.ABSTRACTThe pediatric population with comorbidities is a high-risk group for severe coronavirus disease 2019 (COVID-19). As of January 2023, the COVID-19 vaccination rate for at least two doses among Korean children 5-11 years is low at 1.1%. We summarized the COVID-19 vaccination status for the pediatric population (5-17 years) with comorbidities through July 2022 using the National Health Insurance Service database. Pediatric patients with comorbidities had higher vaccination rates than the general pediatric population (2.4% vs. 1.1% in 5-11-year-o...
Source: J Korean Med Sci - August 15, 2023 Category: General Medicine Authors: Areum Shin Dong Wook Kim Young-Eun Kim Doo Ri Kim Jaehun Jung Yae-Jean Kim Source Type: research
A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea
CONCLUSION: As the COVID-19 variants and risk group-specific durable efficacy, toxicity (and/or resistance) and optimal dosing of Evusheld remain uncertain, better empirical estimates to inform these values in different epidemiological contexts are needed. These results may help decision-makers prioritize resources toward more equitable and effective COVID-19 control efforts.PMID:37582500 | DOI:10.3346/jkms.2023.38.e250
Source: J Korean Med Sci - August 15, 2023 Category: General Medicine Authors: Youngji Jo Sun Bean Kim Jaehun Jung Source Type: research
COVID-19 Vaccination Status Among Korean Pediatric Population With Comorbidities
J Korean Med Sci. 2023 Aug 14;38(32):e248. doi: 10.3346/jkms.2023.38.e248.ABSTRACTThe pediatric population with comorbidities is a high-risk group for severe coronavirus disease 2019 (COVID-19). As of January 2023, the COVID-19 vaccination rate for at least two doses among Korean children 5-11 years is low at 1.1%. We summarized the COVID-19 vaccination status for the pediatric population (5-17 years) with comorbidities through July 2022 using the National Health Insurance Service database. Pediatric patients with comorbidities had higher vaccination rates than the general pediatric population (2.4% vs. 1.1% in 5-11-year-o...
Source: J Korean Med Sci - August 15, 2023 Category: General Medicine Authors: Areum Shin Dong Wook Kim Young-Eun Kim Doo Ri Kim Jaehun Jung Yae-Jean Kim Source Type: research
Effects of COVID-19 and Influenza Vaccination on Rheumatic Diseases: Results From a Survey of Patient-Reported Outcomes After Vaccination
CONCLUSION: The results of the survey of patients with ARD revealed that patient-reported AEs and underlying disease flares after receiving the COVID-19 vaccine were significantly higher than those after the influenza vaccine.PMID:37582497 | DOI:10.3346/jkms.2023.38.e247
Source: J Korean Med Sci - August 15, 2023 Category: General Medicine Authors: Ji-Won Kim Ju-Yang Jung Chang-Hee Suh Young-Min Ye Hyoun-Ah Kim Source Type: research
A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea
CONCLUSION: As the COVID-19 variants and risk group-specific durable efficacy, toxicity (and/or resistance) and optimal dosing of Evusheld remain uncertain, better empirical estimates to inform these values in different epidemiological contexts are needed. These results may help decision-makers prioritize resources toward more equitable and effective COVID-19 control efforts.PMID:37582500 | DOI:10.3346/jkms.2023.38.e250
Source: J Korean Med Sci - August 15, 2023 Category: General Medicine Authors: Youngji Jo Sun Bean Kim Jaehun Jung Source Type: research
COVID-19 Vaccination Status Among Korean Pediatric Population With Comorbidities
J Korean Med Sci. 2023 Aug 14;38(32):e248. doi: 10.3346/jkms.2023.38.e248.ABSTRACTThe pediatric population with comorbidities is a high-risk group for severe coronavirus disease 2019 (COVID-19). As of January 2023, the COVID-19 vaccination rate for at least two doses among Korean children 5-11 years is low at 1.1%. We summarized the COVID-19 vaccination status for the pediatric population (5-17 years) with comorbidities through July 2022 using the National Health Insurance Service database. Pediatric patients with comorbidities had higher vaccination rates than the general pediatric population (2.4% vs. 1.1% in 5-11-year-o...
Source: J Korean Med Sci - August 15, 2023 Category: General Medicine Authors: Areum Shin Dong Wook Kim Young-Eun Kim Doo Ri Kim Jaehun Jung Yae-Jean Kim Source Type: research
Effects of COVID-19 and Influenza Vaccination on Rheumatic Diseases: Results From a Survey of Patient-Reported Outcomes After Vaccination
CONCLUSION: The results of the survey of patients with ARD revealed that patient-reported AEs and underlying disease flares after receiving the COVID-19 vaccine were significantly higher than those after the influenza vaccine.PMID:37582497 | DOI:10.3346/jkms.2023.38.e247
Source: J Korean Med Sci - August 15, 2023 Category: General Medicine Authors: Ji-Won Kim Ju-Yang Jung Chang-Hee Suh Young-Min Ye Hyoun-Ah Kim Source Type: research
